Xeris Biopharma (XERS) reported $54.27 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.3%. EPS of -$0.06 for the same period compares to -$0.09 a year ago.The reported revenue represents a surprise of +5.09% over the Zacks Consensus Estimate of $51.64 million. With the consensus EPS estimate being -$0.09, the EPS surprise was +33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare t ...